<DOC>
	<DOCNO>NCT00305162</DOCNO>
	<brief_summary>The primary objective study demonstrate efficacy cangrelor superior , least non-inferior , clopidogrel subject require PCI .</brief_summary>
	<brief_title>A Clinical Trial Demonstrate Efficacy Cangrelor</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Cangrelor</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>INCLUSION CRITERIA To include study , subject must meet following criterion : Angiography demonstrate atherosclerosis amenable treatment percutaneous coronary intervention ( PCI ) without stent implantation diagnosis Acute Coronary Syndrome ( ACS ) elevate cardiac marker ischemic chest discomfort w/electrocardiogram change + age &gt; 65 diabetes STelevation MI . EXCLUSION CRITERIA Subjects exclude study present following : 1 . Not candidate PCI 2 . Increased bleed risk : ischemic stroke within last year previous hemorrhagic stroke , tumor , cerebral arteriovenous malformation , intracranial aneurysm ; recent ( &lt; 1 month ) trauma major surgery ( include bypass surgery ) ; currently receive warfarin , active bleeding 3 . Impaired hemostasis : know International Normalized Ratio ( INR ) &gt; 1.5 screening ; past present bleed disorder ( include congenital bleeding disorder von Willebrand 's disease hemophilia , acquire bleeding disorder , unexplained clinically significant bleed disorder ) , thrombocytopenia ( platelet count &lt; 100,000/ÂµL ) , history thrombocytopenia neutropenia associate clopidogrel 4 . Severe hypertension adequately control antihypertensive therapy time randomization 5 . Receipt fibrinolytic therapy 12 hour precede randomization 6 . Receipt clopidogrel dose exceed maintenance dose ( ie , &gt; 75 mg ) time 5 day precede randomization 7 . Inability swallow study capsule 8 . Glycoprotein IIb/IIIa ( GPI ) Inhibitor usage within previous 12 hour [ applicable unstable angina ( UA ) nonSTelevation myocardial infarction ( NSTEMI ) patient ] Subjects exclude reason may rescreened participation time exclusion characteristic change .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Acute Coronary Syndrome ( ACS )</keyword>
	<keyword>Percutaneous Coronary Intervention ( PCI )</keyword>
	<keyword>non-ST-segment elevation myocardial infarction ( NSTEMI )</keyword>
	<keyword>ST-segment elevation myocardial infarction ( STEMI )</keyword>
</DOC>